G'day colinf,
Yes, the ongoing development of the transdermal patch by Sequella is old news. In fact I believe that it was announced by Sequella in January 2002.
The contract that they have awarded to Progen is new news (announced yesterday) and is probably good news for Progen.
It has absolutely no relevance to CST, however. The Sequella transdermal patch test is a test for active TB, wheras the Quantiferon test from Cellestis (CST) is a test for latent TB.
From www.sequella.com:
The Transdermal Patch is a diagnostic with the potential to identify patients with active TB, distinguishing them from those who have been latently infected or vaccinated.
Unlike the tuberculin skin test, this patch specifically identifies patients with active tuberculosis who are therefore infectious. The patch is configured like a simple Band-Aid®, and delivers a soluble TB protein directly through the skin.
If you need to know more, just ask.
Add to My Watchlist
What is My Watchlist?
